Drug Trial Radar · NCT06863272
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Jul 3, 2025
Primary completion
Oct 1, 2031
Study completion Oct 1, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Mar 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: * The safety of the study treatment and if people tolerate it. * A safe dose level of I-DXd that can be used with other treatments. * Participant levels of prostate specific antigen (PSA) during treatment.
Conditions
- Castration-Resistant Prostatic Cancer
- Metastasis
Interventions
DocetaxelDrug
Administered via Intravenous (IV) infusion at a specified dose on specified days
Ifinatamab DeruxtecanDrug
Administered via IV infusion at a specified dose on specified days
OpevesostatDrug
Administered orally at a specified dose on specified days
AbirateroneDrug
Administered orally at a specified dose on specified days
EnzalutamideDrug
Administered orally at a specified dose on specified days
Rescue MedicationDrug
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms OnlyTime frame: Up to approximately 21 days
- Efficacy Phase: Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 54 months
- Efficacy Phase: Number of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to approximately 24 months
- Efficacy Phase: Prostate-Specific Antigen (PSA) response rateTime frame: Up to approximately 54 months
- Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms OnlyTime frame: Up to approximately 21 days
- Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE) - Combination Arms OnlyTime frame: Up to approximately 21 days
- Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AE - Combination Arms OnlyTime frame: Up to approximately 21 days
Locations
82 sites in 19 countries. Site status is shown where the registry gives one.
UCLA Hematology & Oncology ( Site 0003)
Los Angeles, California · Recruiting
University of California-Irvine Medical Center ( Site 0016)
Orange, California · Recruiting
UCSF Medical Center at Mission Bay ( Site 0034)
San Francisco, California · Recruiting
MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)
Washington D.C., District of Columbia · Recruiting
University of Michigan ( Site 0021)
Ann Arbor, Michigan · Recruiting
Memorial Sloan Kettering Cancer Center ( Site 0006)
New York, New York · Recruiting
UPMC Hillman Cancer Center ( Site 0014)
Pittsburgh, Pennsylvania · Recruiting
The West Clinic, PLLC dba West Cancer Center ( Site 0005)
Germantown, Tennessee · Recruiting
Fred Hutchinson Cancer Center ( Site 0013)
Seattle, Washington · Recruiting
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200)
La Rioja, Argentina · Recruiting
Instituto Alexander Fleming ( Site 0202)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Macquarie University-MQ Health Clinical Trials Unit ( Site 0801)
Macquarie University, New South Wales, Australia · Recruiting
IPITEC ( Site 0275)
São Paulo, Brazil · Recruiting
IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0269)
São Paulo, Brazil · Recruiting
Liga Norte Riograndense Contra o Câncer ( Site 0271)
Natal, Rio Grande do Norte, Brazil · Recruiting
Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0270)
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Hospital Moinhos de Vento ( Site 0278)
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0268)
Bragança Paulista, São Paulo, Brazil · Recruiting
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) ( Site 0273)
Ribeirão Preto, São Paulo, Brazil · Recruiting
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0263)
São José do Rio Preto, São Paulo, Brazil · Recruiting
Hospital Alemao Oswaldo Cruz ( Site 0279)
São Paulo, São Paulo, Brazil · Recruiting
BC Cancer - Vancouver Center ( Site 0103)
Vancouver, British Columbia, Canada · Recruiting
Sunnybrook Research Institute ( Site 0109)
Toronto, Ontario, Canada · Recruiting
Princess Margaret Cancer Centre ( Site 0102)
Toronto, Ontario, Canada · Recruiting
Jewish General Hospital ( Site 0108)
Montreal, Quebec, Canada · Recruiting
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0107)
Sherbrooke, Quebec, Canada · Recruiting
Clinica Universidad Catolica del Maule ( Site 0236)
Talca, Maule Region, Chile · Recruiting
Fundación Arturo López Pérez ( Site 0232)
Santiago, Region M. de Santiago, Chile · Recruiting
Centro de Oncología de Precisión ( Site 0241)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill ( Site 0231)
Santiago, Region M. de Santiago, Chile · Recruiting
ONCOCENTRO APYS ( Site 0234)
Viña del Mar, Valparaiso, Chile · Recruiting
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 0498)
Bordeaux, Gironde, France · Recruiting
Centre Oscar Lambret ( Site 0495)
Lille, Nord, France · Recruiting
Institut De Cancerologie De L Ouest ( Site 0494)
Saint-Herblain, Pays de la Loire Region, France · Recruiting
Centre Hospitalier de la Cote Basque ( Site 0496)
Bayonne, Pyrenees-Atlantiques, France · Recruiting
centre hospitalier lyon sud ( Site 0497)
Pierre-Bénite, Rhone, France · Recruiting
Universitaetsklinikum Hamburg-Eppendorf ( Site 0524)
Hamburg, Germany · Recruiting
NCT ( Site 0528)
Heidelberg, Baden-Wurttemberg, Germany · Recruiting
Universitaetsklinikum Ulm. ( Site 0530)
Ulm, Baden-Wurttemberg, Germany · Recruiting
Universitaetsklinikum Jena ( Site 0525)
Jena, Thuringia, Germany · Recruiting
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.